Health insurance; parity of coverage for oral chemotherapy medications. (SB383)

Introduced By

Sen. Jill Holtzman Vogel (R-Winchester) with support from co-patron Del. Chris Peace (R-Mechanicsville)

Progress

Introduced
Passed Committee
Passed House
Passed Senate
Signed by Governor
Became Law

Description

Health insurance; parity of coverage for oral chemotherapy medications. Requires health insurers, health care subscription plans, and health maintenance organizations, whose policies provide coverage for cancer chemotherapy treatment, to provide coverage for a prescribed, orally administered anticancer medication on a basis no less favorable than that on which it provides coverage for intravenously administered or injected anticancer medications. Such a policy, contract, or plan shall not require a higher copayment, deductible, or coinsurance amount for a prescribed, orally administered anticancer medication than what it requires for an intravenously administered or injected anticancer medication that is provided, regardless of formulation or benefit category determination by the insurer, corporation, or health maintenance organization. The measure applies to the state employees' health insurance plan and to the local choice health program. The measure replaces a provision enacted in 2012 that requires health insurers, health care subscription plans, and health maintenance organizations whose policies, contracts, or plans include coverage for intravenously administered, injected, and orally administered anticancer drugs to consistently apply the criteria for establishing cost sharing applicable to orally administered cancer chemotherapy drugs and cancer chemotherapy drugs that are administered intravenously or by injection. Read the Bill »

Status

01/11/2016: Awaiting a Vote in the Commerce and Labor Committee

History

DateAction
01/11/2016Prefiled and ordered printed; offered 01/13/16 16102574D
01/11/2016Referred to Committee on Commerce and Labor
01/29/2016Impact statement from SCC (SB383)
02/01/2016Impact statement from SCC (SB383)
02/05/2016Impact statement from SCC (SB383)
02/08/2016Continued to 2017 in Commerce and Labor (10-Y 0-N) (see vote tally)